Abstract: The present invention relates to a method and kit for removing linker self-linking products during sequencing library construction and for constructing a sequencing library. In particular, provided is a method and kit for the selective cleavage of DNA double strands and DNA single strands, a method and kit for selective cleavage by using DNA-RNA-DNA:cDNA heterozygous chains and DNA:cDNA double strands, and a method and kit for DNA and RNA library co-construction.

Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.

Abstract: Provided are methods of using a MYC gene as a biomarker for predicting therapeutic efficacy of survivin inhibitors such as YM155 monobromide in cancer therapy, and related kits, compositions, and methods for diagnosing and treating cancer in a subject in need thereof.

Abstract: Provided are cytokine fusion proteins comprising a first cytokine fused to a second cytokine, for example, interleukin-2 (IL-2) or interferon-? (IFN-?) fused to the N-terminus of tumor necrosis factor-? (TNF-?), and related compositions and methods of use thereof for treating cancers, either as standalone agents or in combination with autologous tumor vaccines and/or immune checkpoint modulatory agents.

Abstract: Provided are methods of using a MYC gene as a biomarker for predicting therapeutic efficacy of survivin inhibitors such as YM155 monobromide in cancer therapy, and related kits, compositions, and methods for diagnosing and treating cancer in a subject in need thereof.

Abstract: Provided is the use of Androgen Receptor-Low/Negative (ARlow/?) status as a biomarker for the efficacy of YM155 monobromide in cancer therapy, and related kits, compositions, and methods for diagnosing and treating cancer in a subject in need thereof.

Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.

Abstract: Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.

Abstract: It relates to a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

Abstract: Disclosed is an integrated device for faeces sampling and occult blood detection, which has functions of quantitative collection, dissolution, filtration, detection with immune test strips of the faecal sample, and is convenient to carry and operate, and the device does not leak any liquid during storage, transportation and detection. The device can accurately collect a constant sample with no pollution and leakage, and can quickly determine results of occult blood without the aid of other items. The device can detect faecal occult blood at any time and at any place, can help to overcome the problem of low rate of inspection due to the inconvenience of faeces submission and inspection, further promote the detection of faecal occult blood, and can improve the early diagnosis and screening rate of colorectal cancer of the population.

Abstract: Provided is a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.

Abstract: Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.

Abstract: Provided are methods of using an anti-cancer agent's cell cycle-related, cell-killing activity to identify it as an effective combination with YM155 monobromide for treating MYC-associated cancers, and related kits, compositions, methods of screening, and methods for treating cancer in a subject in need thereof.

Abstract: Provided are combination therapies and secondary biomarkers for treating MYCC-associated diffuse large B-cell lymphoma (DLBCL) with YM155-based therapies, and related kits, compositions, and methods of use thereof.

Abstract: Disclosed is an integrated device for faeces sampling and occult blood detection, which has functions of quantitative collection, dissolution, filtration, detection with immune test strips of the faecal sample, and is convenient to carry and operate, and the device does not leak any liquid during storage, transportation and detection. The device can accurately collect a constant sample with no pollution and leakage, and can quickly determine results of occult blood without the aid of other items. The device can detect faecal occult blood at any time and at any place, can help to overcome the problem of low rate of inspection due to the inconvenience of faeces submission and inspection, further promote the detection of faecal occult blood, and can improve the early diagnosis and screening rate of colorectal cancer of the population.

Abstract: Disclosed is an integrated device for faeces sampling and occult blood detection, which has functions of quantitative collection, dissolution, filtration, detection with immune test strips of the faecal sample, and is convenient to carry and operate, and the device does not leak any liquid during storage, transportation and detection. The device can accurately collect a constant sample with no pollution and leakage, and can quickly determine results of occult blood without the aid of other items. The device can detect faecal occult blood at any time and at any place, can help to overcome the problem of low rate of inspection due to the inconvenience of faeces submission and inspection, further promote the detection of faecal occult blood, and can improve the early diagnosis and screening rate of colorectal cancer of the population.

Abstract: The present disclosure relates to compositions and methods for detecting and/or identifying the genotype of a human papillomavirus (HPV) in a biological sample obtained from a subject in need thereof. Particularly, the present disclosure provides primers, probes and kits for simultaneously detecting multiple HPV genotypes in a single-tube PCR reaction.